<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883190</url>
  </required_header>
  <id_info>
    <org_study_id>21-1340</org_study_id>
    <nct_id>NCT04883190</nct_id>
  </id_info>
  <brief_title>Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial</brief_title>
  <acronym>SubFSC19-KN</acronym>
  <official_title>Physical and Mental Fatigue a Long COVID-19 Symptom - Substudy of FSC19-KN Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hegau-Bodensee-Klinikum Singen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hegau-Bodensee-Klinikum Singen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, controlled follow-up observation of SARS-CoV-2 positive patients with regard to&#xD;
      the aspect of fatigue (cognitive / motor) and psychological disorders in the areas of&#xD;
      anxiety, depression and somatization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent is given, questionnaires will be obtained 6 months and 12 months after&#xD;
      infection. For analyzing cognitive and motor fatigue, classified in mildly, moderately or&#xD;
      severely fatigue the questionnaire will be calculated by The Fatigue Scale for Motor and&#xD;
      Cognitive Functions (FSMC).&#xD;
&#xD;
      And the occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome&#xD;
      measured by Brief Patient Health Questionnaire.&#xD;
&#xD;
      The FSC19-KN trial already included patients with positive test for SARS-CoV-2 by PCR and&#xD;
      volunteers with negative SARS-CoV-2 antibody testing. Verification of exclusion criteria had&#xD;
      been completed in the main trial FSC19-KN. After the informed consent to participation in the&#xD;
      sub-study is given all inclusion modalities are fulfilled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of fatigue</measure>
    <time_frame>6 month after infection</time_frame>
    <description>Evaluate cognitive and motor fatigue classified in mildly, moderately or severely fatigue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of fatigue</measure>
    <time_frame>12 month after infection</time_frame>
    <description>Evaluate cognitive and motor fatigue classified in mildly, moderately or severely fatigue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome.</measure>
    <time_frame>6 month after infection</time_frame>
    <description>analyzed by PHQ-D (brief)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome.</measure>
    <time_frame>12 month after infection</time_frame>
    <description>analyzed by PHQ-D (brief)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>1. after SARS-CoV-2 infection</arm_group_label>
    <description>All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.&#xD;
We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. control group with negative antibody test</arm_group_label>
    <description>All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.&#xD;
We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fulfilling Questionaires</intervention_name>
    <description>Fulfilling Questionaires PHQ-D (brief) and FSMC</description>
    <arm_group_label>1. after SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>2. control group with negative antibody test</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Within the FSC19-KN trial up to 250 SARS-CoV-2 positive patients and 250 volunteers without&#xD;
        SARS-CoV-2 infection are included.&#xD;
&#xD;
        We plan to contact all attendees of the FSC19-KN trial which gave permission to contact via&#xD;
        e-mail.&#xD;
&#xD;
        They will be asked to contribute the sub-study by declaring their informed consent online.&#xD;
        Only if their agreement of participation is given, they can fill in our online&#xD;
        questionnaire.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient must meet ALL of the following criteria.&#xD;
&#xD;
          1. Participation in the FSC19-KN study&#xD;
&#xD;
          2. Consent to participate in the survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Failure to give consent to the survey&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc Kollum, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hegau-Bodensee-Klinikum Singen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Kollum, PD Dr.</last_name>
    <phone>00497731892600</phone>
    <email>marc.kollum@glkn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Geng</last_name>
    <email>sabrina.geng@glkn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hegau Bodensee Klinikum Singen</name>
      <address>
        <city>Singen</city>
        <state>BW</state>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Kollum, PD Dr.</last_name>
      <phone>00497731892600</phone>
      <email>marc.kollum@glkn.de</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Zimmermann</last_name>
      <phone>00497731892674</phone>
      <email>heidi.zimmermann@glkn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 23, 2021</last_update_submitted>
  <last_update_submitted_qc>May 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatigue</keyword>
  <keyword>Covid-19 Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The aim is to publish the results in a peer reviewed medical journal without sharing any participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

